Objective. The interaction between neutrophils and activation of alternative complement pathway plays a critical role in the pathogenesis of ANCA-associated vasculitis (AAV). MPO, which can be released from ANCA-stimulated neutrophils, was recently demonstrated to be capable of activating the alternative complement pathway. Here we aimed to investigate the interaction between MPO and factor H (FH), a key regulator of the alternative pathway, and its effect on the functional activities of FH.
Introduction
ANCA-associated vasculitis (AAV) comprises a group of systemic autoimmune diseases characterized by circulating autoantibodies against constituents of neutrophils, especially PR3 and MPO. Accumulating evidence from both animal studies and clinical studies has demonstrated the critical role of alternative complement pathway activation in the pathogenesis of AAV [18] . Activation of the alternative complement pathway amplifies the recruitment, priming and activation of neutrophils, creating a self-amplifying inflammatory loop that results in destructive necrotizing vascular injury [3, 9, 10] . Unlike the classic and lectin pathways, the alternative pathway of the complement system is characterized by spontaneous activation and self-amplification and is tightly regulated by several fluid-phase and cell-bound complement regulators under normal circumstances. How the alternative complement pathway is activated in AAV has not yet been fully elucidated.
A series of in vitro studies showed that ANCA-stimulated neutrophils release substances that activate the complement system in serum [1, 3] . Interestingly, a recent study showed that MPO, the main ANCA autoantigen in neutrophils, is capable of activating the alternative complement pathway by interacting with properdin, the only positive regulator of the alternative pathway [11] . Meanwhile, our previous study found that MPO could block the binding between monomeric CRP (mCRP) and factor H, which might inhibit the negative regulation of alternative complement activation in AAV [12] . Complement factor H, composed of 20 short consensus repeats (SCRs), is a key regulator of the alternative pathway that strictly controls the alternative complement activation in circulation and at the host cell surface by accelerating the decay of C3 convertase (C3bBb) and by acting as a cofactor for factor Imediated cleavage of C3b [13, 14] . The four N-terminal domains mediate complement regulation and the two C-terminal domains are relevant for host cell attachment [1517] . Our recent studies suggested a potential role of complement factor H in the development of AAV [18, 19] . These led us to raise the question of whether MPO interacts with FH and influences the functional activity of FH. To address this issue, we characterized the staining of MPO and FH in neutrophil extracellular traps (NETs) and in kidney biopsies from patients with AAV. Then we explored the binding between MPO and FH and further investigated the influence of MPO on the complement regulatory activity of FH.
Methods

Immunofluorescence
Increasing evidence has suggested a pathogenic role of NETs in the development of AAV. In particular, NETs induced by ANCA have been demonstrated to be capable of activating the alternative complement pathway [20] . Therefore deposition of FH on NETs was examined in the current study. NETs were induced using serum of patients with AAV, as previously described [21] . Briefly, neutrophils were isolated from heparinized whole blood of healthy blood donors. Neutrophils were seeded on eight-well chamber slides in Roswell Park Memorial Institute 1640 supplemented with 0.5% heat-inactivated foetal bovine serum at a density of 10 5 cells per well and allowed to adhere for 1 h at 37 C. Then, neutrophils were treated with serum of patients with AAV at a final concentration of 6% for 3 h at 37 C for NETs induction [21] , followed by fixing with 4% paraformaldehyde. After washing with PBS, the samples were permeabilized for 1 min with 0.5% Triton X-100 in PBS. MPO and FH were stained with mouse anti-human MPO mAb (Abcam, Cambridge, MA, USA) and goat anti-human FH polyclonal antibody (Calbiochem, Darmstadt, Germany), respectively. Isotype controls for staining antibodies were performed by incubating with normal mouse IgG1 (Abcam) and normal goat IgG (Calbiochem). Fluorescent detection was achieved by incubation with Cy3-conjugated donkey anti-mouse IgG and Alexa Fluor 488conjugated donkey anti-goat IgG. DNA was stained with 4 0 ,6-diamidino-2-phenylindole (ZSGB-BIO, Beijing, China). Immunofluorescence staining was visualized in a confocal microscope (Carl Zeiss, Oberkochen, Germany).
To examine the deposition of MPO and FH in the kidney, paraffin-fixed sections (2 mm) from renal biopsy specimens of patients with AAV were dewaxed, rehydrated and pre-treated with pepsin for antigen retrieval. Renal tissues obtained from the normal part of nephrectomized kidneys (because of renal carcinoma) were used as normal controls and tissue from a patient with diabetic nephropathy was included as the disease control. After blocking with PBS containing 3% BSA for 1 h, the sections were incubated with primary antibodies against human FH and MPO or an endothelial marker, CD34 (Abcam), overnight at 4 C followed by the corresponding secondary antibodies as described above. As isotype controls, primary antibodies were replaced by normal goat IgG with mouse IgG1 or normal rabbit IgG (Sigma, St Louis, MO. USA), respectively.
Informed consent was obtained from each participant. The study was in compliance with the Declaration of Helsinki and was approved by the ethics committees of Peking University First Hospital.
Interaction of MPO with FH and recombinant FH fragments measured by ELISA Microtitre plate wells were coated with 2 mg/ml MPO in PBS by overnight incubation at 4 C. A 0.2% gelatin was coated as negative controls. Non-specific binding to the plates was blocked with 0.2% gelatin. After washing, increasing concentrations of FH were added to the wells followed by detection using a polyclonal antibody against FH and then alkaline phosphataseconjugated rabbit antigoat IgG (Sigma). P-nitrophenyl phosphate (Sigma) substrate solution was used to visualize antibody binding and the absorbance was read at 405 nm. To identify the binding site for MPO on FH, full-length FH and recombinant FH fragments consisting of SCRs 14, 56, 7, 810, 1114, 1518 and 1920 (GenScript, Piscataway, NJ, USA) were added to MPO-coated microtitre plates at the same molar concentrations (100 nM). Wells coated with 0.2% gelatin were set as negative controls. Bound FH and FH fragments were detected using goat anti-human FH antibody, which has been demonstrated to recognize the full-length FH and these SCRs of FH (see supplementary Fig. S1 , available at Rheumatology online) [22] . Bound SCR1920 was also detected using the mAb C18 (Enzo Life Sciences, Lö rrach, Germany), a mAb against SCR20 of FH [23] .
Surface plasmon resonance (SPR) analysis of MPO binding to FH The interaction between MPO and FH as well as FH fragments was further characterized by SPR in a Biacore T200 using S series CM5 sensor chips (GE Healthcare, Chicago, IL, USA) and analysed with the Biacore T200 evaluation software. MPO was immobilized on a CM5 chip using the amine-coupling procedure. FH and recombinant fragments of FH were allowed to flow across the chip in Tris buffer containing 10 mM Tris and 140 mM NaCl, pH 7.4 with 0.05% surfactant P-20. As controls, all binding tests were also performed using a blank chip activated and deactivated under identical conditions. After each binding experiment, the surface was regenerated by a short injection of 0.5 M NaCl. The binding kinetics of FH and the identified FH fragments for MPO binding were also analysed using chips immobilized with FH and relevant FH fragments, respectively. A chip coupled with an unrelated protein (gelatin) was used as the negative control. The surface was regenerated with 10 mM glycine-HCl, pH 2.0.
Influence of MPO on the interaction between FH and C3b
According to our previous findings, the mean concentration of MPO in the supernatants of ANCA activated neutrophils was $2 mg/ml [12] . Moreover, at this concentration, MPO largely inhibited the binding between mCRP and factor H [12] . Therefore a final concentration of 2 mg/mL MPO was applied in further experiments. Microtitre plate wells were coated with 4 mg/ml C3b (Calbiochem) in PBS overnight at 4 C. Serial dilutions of FH were incubated with 2 mg/ml MPO or buffer for 1 h at 37 C. In some experiments, 4 mg/ ml FH were incubated with serial dilutions of MPO covering 2 mg/ml. After washing the plate, samples were transferred to individual wells for 1 h at 37 C. Bound FH was detected as described above.
C3 convertase decay assay
Solid-phase alternative pathway C3 convertase was assembled on immobilized C3b in microtitre plate wells, as described previously [24] . Decay acceleration was analysed by the addition of increasing concentrations (2.5, 5 and 10 mg/ml) of FH or human serum albumin as a control for 30 min at 37 C. To assess the influence of MPO on FH decay-accelerating activity, FH was pre-incubated with or without 2 mg/ml MPO for 1 h at 37 C. The remaining intact convertase was determined using a goat anti-factor B antiserum (Calbiochem).
Cofactor assays
To investigate whether MPO influences the cofactor activity of FH, 4 mg/ml FH with or without 2 mg/ml MPO were incubated with C3b (50 mg/ml) and factor I (10 mg/ml) for 10 min at 37 C in a final volume of 20 ml [25] . The reactions were stopped by adding reducing loading buffer with 5% b-mercaptoethanol. Samples were loaded onto 11% SDS-PAGE gels, separated by electrophoresis and subjected to western blot. C3 fragments were revealed using rabbit polyclonal antibody to human C3c (Dako, Glostrup, Denmark).
Based on the previous study, the full-length FH is hypothesized to adopt, preferentially, a latent conformation accounting for low affinity for C3b, but a higher-affinity 'activated' conformation is stabilized by interaction with C3b and molecular markers on a self-surface [26] . Therefore the effect of MPO on the cofactor activity of FH on surfaces was analysed using the human basement membrane extract MaxGel (Sigma) and human renal glomerular endothelial cells (HRGECs; ScienCell Research Laboratories, San Diego, CA, USA), respectively. To assay cofactor activity on MaxGel [27] , 40 ml of 1 mM FH pre-incubated with 2 mg/ml MPO or buffer were added to wells coated with MaxGel [diluted 1:40 in Tris-buffered saline (TBS) containing 2 mM CaCl 2 and 1 mM MgCl 2 ] for 1 h at 37 C. After washing, 50 mg/ml C3b and 10 mg/ml factor I diluted in TBS were added in 40 ml to the wells and incubated for 30 min at 37 C. C3 cleavage products in the supernatants were identified, as described above. In order to investigate the effect on the host cell surface, the cofactor activity of FH on HRGECs was measured according to the previously described method [27] , with some minor modifications. Briefly, endothelial cells growing on 96-well cell culture plates were incubated with 1 mM FH pre-incubated with 2 mg/ml MPO or buffer in a final volume of 40 ml in Dulbecco's PBS at 37 C for 1 h. After washing, cells were incubated with 50 mg/ml C3b and 10 mg/ml factor I in 40 ml for 30 min at 37 C. Supernatants were analysed for C3b cleavage, as described above.
Haemolysis assays
To assess the influence of MPO on the protective ability of FH against complement-mediated haemolysis of sheep erythrocytes, FH pre-incubated with MPO or buffer was added to sheep erythrocytes in the presence of 4 mg mAb OX24 (binding to SCR5 of FH) with 15% normal human serum in a final volume of 200 ml, as described previously [23] . The reactions were incubated at 37 C for 30 min, the erythrocytes were sedimented by centrifugation and the released haemoglobin was measured in the supernatants at 414 nm. C3a and C5a in the supernatants were measured using commercial ELISA kits according to the manufacturer's instructions (Quidel, San Diego, CA, USA).
Statistical analysis
Data were presented as mean (S.D.). Statistical differences between groups were determined by t test or analysis of variance as appropriate. P-values <0.05 were considered statistically significant. Analysis was performed with SPSS statistical software (version 13.0; SPSS, Chicago, IL, USA).
Results
Immunostaining of FH and MPO in NETs and renal biopsies of AAV NETs were induced by serum from patients with AAV, as determined by decondensed extracellular DNA decorated https://academic.oup.com/rheumatology with extracellular MPO. We found that FH deposited in NETs and merged with the staining of MPO (Fig. 1) . The renal biopsies of patients with AAV demonstrated positive staining of FH distributed along endothelium cells of the glomeruli, co-localizing with the staining of endothelial cells (CD34). MPO appeared to decorate the glomerular capillaries and was closely adjacent to the staining of FH. In some areas of the glomerulus, co-localization of MPO and FH on endothelial cells was observed (Fig. 2) . Nevertheless, glomerulus from normal controls and glomerulus from a patient with diabetic nephropathy demonstrated little staining of FH and no intraglomerular MPO with intact CD34 + endothelial cells. Staining with isotype controls is shown in supplementary Fig. S2 , available at Rheumatology online.
Binding between FH and MPO
The binding between FH and MPO was determined by ELISA using a polyclonal antibody against FH. An increasing concentration of FH showed dose-dependent binding to coated MPO (Fig. 3A) . To identify the binding sites for MPO on FH, we assessed the binding of recombinantly expressed FH fragments that span through the whole molecule to coated MPO. SCR14 of FH was identified as containing the major binding site for MPO (Fig. 3B) . To rule out the possibility that FH was interacting with traces of DNA that still could not be completely isolated from MPO during purification, MPO was treated with 010 units of DNase-1 (Sigma) prior to FH incubation; no obvious difference in ), respectively. Using the same chip, SCR14 of FH was confirmed to contain the major binding site for MPO with an apparent KD of 5.95 Â 10 À9 M, which was comparable to the full-length FH (Fig. 3CE) . The calculated apparent association and dissociation constants were 9.68 Â À4 ), respectively. Consistently, MPO bound to FH and SCR14 coupled chips with similar affinities, which was 1.28 Â 10 À9 M and 3.66 Â 10 À10 M, respectively ( Fig. 3F and G) .
MPO inhibits the interaction of FH with C3b and the functional activity of FH in the regulation of C3b
Interaction of FH with C3b is essential for the regulatory activities of FH, as it mediates the decay-accelerating and cofactor activities of FH. Therefore we first investigated whether the FHC3b interaction could be altered in the presence of MPO. MPO inhibited the binding of FH to C3b in a dose-dependent manner. By incubating increasing concentrations of FH mixed with 2 mg/ml MPO in C3b-coated wells, we found the FH bound dose-dependently to C3b, but the interaction between FH and C3b was largely inhibited in the presence of MPO (P < 0.001; Fig. 4A and B). Then we tested the influence of the MPOFH interaction on the decay-accelerating activity of FH. The results showed that FH accelerated the decay of C3 convertase (C3bBb), which was assembled on immobilized C3b, in a dose-dependent manner (Fig. 4C ). In the presence 2 mg/ml MPO, the decay-accelerating activity of FH was significantly weakened (Fig. 4D) .
To explore whether MPO interferes with the cofactor activity of CFH upon C3b inactivation, the fluid phase cofactor activity of FH in the presence of MPO was assayed. MPO inhibited the cofactor activity of FH, as evidenced by the increased density of the uncleaved a 0 108 band and the decreased density of the cleaved a 0 43 band (Fig. 5A ). Densitometric analyses of the relative intensity of the a 0 43 band showed that the fluid phase cofactor activity of FH was decreased by $40% in the presence of 2 mg/ml MPO [100% (S.D. 0.00) vs 58.98% (S.D. 5.13), P < 0.001] (Fig. 5B) . We further found that cofactor activity of FH on human basement membrane extract MaxGel and HRGECs were also inhibited in the presence of 2 mg/ml MPO. Densitometric analyses showed that the cofactor activity of FH on such surfaces was decreased by $30% in the presence of 2 mg/ml MPO [100% (S.D. 0.00) vs 69.38% (S.D. 3.35), P < 0.001; 100% (S.D. 0.00) vs 70.79% (S.D. 2.28), P < 0.001, respectively] (Fig. 5CF) .
Influence of MPO on the protective ability of FH against complement-mediated attack on sheep erythrocytes
We further investigated whether MPO interferes with the protective ability of FH against complement-mediated haemolysis of sheep erythrocytes. Sheep erythrocytes lysis was induced in normal human plasma by mAb OX24, which inhibits the N-terminal complement regulatory domains. A dose-dependent inhibition of this lysis was achieved when FH was added (Fig. 6A) . The addition of MPO did not interfere with the protective ability of FH against sheep erythrocytes lysis induced by mAb OX24 (Fig. 6B) . However, levels of C3a and C5a in the supernatant were significantly higher when FH was pre-incubated with MPO ( Fig. 6C and D) .
Discussion
The interaction between neutrophils and activation of alternative complement pathway plays a pivotal role in the pathogenesis of AAV. An in vitro study showed that neutrophils activated by ANCA release factors capable of activating the complement system and generating C5a [3] . C5a further primes neutrophils for activation by ANCA [3, 9, 10], thus causing a self-amplification loop for ANCA-induced neutrophil activation. Among various neutrophil constituents that could be released upon activation, MPO was previously shown to be capable of activating the alternative complement pathway by interacting with properdin [11] . Our current study found that MPO interacts with the N-terminus of FH and inhibits the complement regulatory activity of FH, indicating a novel path for MPO in activating the complement system. Another interesting finding is that FH deposited in NETs and colocalized with MPO. By demonstrating that the complement regulatory activity of FH was inhibited by MPO, the current study further extended our previous finding that NETs released from ANCA-activated neutrophils are capable of activating the alternative complement pathway [20] . Moreover, by attracting FH binding, it might contribute to the decreased concentration of FH in the plasma of patients with AAV [18] . Based on our previous findings, decreased plasma levels of FH and deficient functional activities of FH were associated with disease activity and circulating levels of complement activation products in AAV [18, 19] , indicating an important role of FH in disease development. Therefore our current finding indicates that the MPOFH interaction may contribute to activation of the alternative complement pathway in AAV patients. Although, ANCA did not influence the binding of MPO to FH, we speculate that it would amplify the effects resulting from the MPOFH interaction. By inhibiting FH, MPO contributes to the generation of more C5a, which would further prime neutrophils for activation by ANCA, resulting in more degranulation of MPO and thus causing a self-fuelling inflammatory amplification loop. In the renal specimens of patients with ANCA-associated glomerulonephritis, MPO was closely adjacent to FH localized to the endothelial surface of the capillary wall, which is consistent with the previous finding that MPO adheres to glomerular endothelial cells and is associated with the extent of endothelial injury in patients with ANCA-associated glomerulonephritis [28] . Although MPO is subendothelially concentrated [28, 29] , there is considerable evidence demonstrating that MPO binds to endothelial cells and lasts for hours [2931] . However, MPO would be transferred from the cell surface to cytoplasm, and possibly nuclear, through an internalization process by endothelial cells [30, 31] . It may account for the current observation that some areas of renal specimens from AAV patients showed co-localization of MPO and FH on endothelial cells, but in most areas of the glomeruli, MPO was subendothelially localized and closely adjacent to FH. Nevertheless, it could not exclude the possibility that the interaction of MPO with FH occurred on the glomerular endothelium. Moreover, given that MPO was able to mediate nitration of tyrosine residues during inflammatory processes [32, 33] , and interestingly, nitration of tyrosines in factor H was recently reported to result in the loss of functional activities in interacting with C3b and cofactor activity for factor Imediated cleavage of C3b [34] , we speculate that MPO adhering to the glomerular endothelium might inhibit the negative regulation of alternative complement activation on endothelial cells. It extends the current understanding that MPO can mediate injury of glomerular capillary walls in AAV by direct oxidative damage and by triggering humoral and cellular immune response [35] .
Although a significant inhibitory effect of MPO on FH-mediated inactivation of C3b on host cell surfaces was observed, no obvious effect can be detected in the haemolytic assays. However, we demonstrated that preincubation of FH with MPO resulted in more C3a and C5a production in the supernatants of haemolytic assays. Regarding the end product of complement activation, it is C5a, not C5b-9, that plays a critical role in the pathogenesis of AAV, as evidenced by the animal study [1, 8] . C5a not only primes neutrophils for activation by ANCA, but also amplifies the neutrophilendothelial cell interactions on the surface of capillary walls [36] . Therefore we suggest that, by contributing to the generation of more C5a, MPOFH interaction may contribute to the disease development of AAV. On the other hand, given that ceruloplasmin, the physiological inhibitor of MPO, exists in the serum, it is reasonable to speculate that it may present as a confounder for the result of the haemolysis assays. However, in patients with AAV, the inhibition of MPO by ceruloplasmin can be reversed by ANCA [37] . It would be of great interest to carry out in vivo studies to investigate the role of MPO on alternative complement activation and regulation in AAV.
Overall, the effect of MPO's interaction on FH cofactor activity and decay accelerating activity or C3a/C5a production is rather modest, which is a limitation of the current study. However, given the fact that the alternative complement pathway is characterized by self-amplification, it was suggested that the very nature of the complement system will amplify these small effects [25] .
Considering that, along with AAV, alternative complement activation has been implicated in various neutrophilmediated diseases, such as bacterial sepsis [38, 39] , the interaction between MPO and FH and its effect on the complement regulatory activity of FH may not be limited in AAV. However, the biological significance of FH in bacterial sepsis is still controversial given that FH was previously reported to contribute to immune invasion of at least 10 pathogenic microbes [4043] . Therefore it would be of great interest to investigate the role of the MPOFH interaction in other diseases.
In conclusion, MPO, which can be released from ANCAstimulated neutrophils, binds to FH and inhibits the complement regulatory activity of FH. The MPOFH interaction may participate in the pathogenesis of AAV by contributing to activation of the alternative complement pathway. 
